Search results for "chino"

showing 10 items of 351 documents

Intra-abdominal Candida spp infection in acute abdomen in a quality assurance (QA)-certified academic setting

2016

AimsTo evaluate the contribution of light microscopy to detecting Candida spp infection in patients with complicated intra-abdominal infections (IAIs) admitted for acute abdomen to a quality assurance (QA)-certified surgical emergency ward.MethodsWe conducted a retrospective study (2008–2012) of 809 abdominal intraoperative or biopsy tissue specimens obtained from patients admitted with acute abdomen and microbiological samples positive for Candida spp. Demographic data, mortality, comorbidities, specimen type, microscopy results, special histological staining performed, antimicrobial therapy were collected and analysed. Any comments at the multidisciplinary team meeting was recorded in min…

AdultMale0301 basic medicinemedicine.medical_specialtyQuality Assurance Health CareSettore MED/17 - Malattie Infettive2734030106 microbiologySettore MED/08 - Anatomia PatologicaPathology and Forensic MedicineYoung Adult03 medical and health sciencesRetrospective StudieInternal medicineBiopsymedicineINFECTIOUS INTESTINAL DISEASEAntifungal AgentEchinocandinSurgical emergencyCandida albicansFluconazoleAgedCandidaAbdomen AcuteAged 80 and overMicroscopybiologymedicine.diagnostic_testFungiGastroenterologyCancerRetrospective cohort studyGeneral MedicineMiddle Agedbiology.organism_classificationAntimicrobialmedicine.diseaseCorpus albicansSurgeryINFECTIONSAcute abdomenCandidiasiFemalemedicine.symptomInfectionHumanJournal of Clinical Pathology
researchProduct

Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry

2009

Patients surviving invasive fungal disease (IFD) and needing further antineoplastic chemotherapy are at high risk of recurrent fungal infection. In the absence of randomised controlled trials in this area, secondary prophylactic regimens are diverse. From 448 patients registered with the Multinational Case Registry of Secondary Antifungal Prophylaxis, we performed an analysis of patients receiving caspofungin (CAS) or itraconazole (ITC). All patients had an underlying haematological malignancy and had been diagnosed with an episode of IFD earlier in their course of treatment. Data collected comprised demographics, underlying disease, first episode of IFD, antifungal prophylaxis, incidence a…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleAspergillosisChemopreventionEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundCaspofunginInternal medicinemedicineHumansAspergillosisPharmacology (medical)RegistriesMycosisAgedFirst episodebusiness.industryIncidence (epidemiology)Stem cell transplantationGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTransplantationTreatment OutcomeInfectious DiseasesMycoseschemistryHematologic NeoplasmsChemoprophylaxisFemaleAntifungal prophylaxisItraconazoleCaspofunginbusinessmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

2010

AbstractThis study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as …

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsNeutropeniaDrug-Related Side Effects and Adverse ReactionsCandidaemia; Caspofungin; Leukaemiamedicine.medical_treatmentAntineoplastic AgentsNeutropeniaEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundPharmacotherapyCandidaemiaCaspofunginInternal medicinemedicineHumansLeukaemiaProspective StudiescaspofunginProspective cohort studyMycosisFungemiaAgedChemotherapyHematologybusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeInfectious DiseaseschemistryHematologic NeoplasmsleukaemiaFemaleCaspofunginbusinessFungemia
researchProduct

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

2007

Summary Background Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentLipoproteinsAmphotericin B/ therapeutic useMicrobial Sensitivity TestsLipoproteins/ therapeutic usePeptides CyclicEchinocandinsLipopeptideschemistry.chemical_compoundDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BPeptides Cyclic/ therapeutic usemedicineHumansAdverse effectMycosisFungemiaCandidiasis/complications/ drug therapy/microbiologyAPACHEAgedddc:616Aged 80 and overVoriconazolebusiness.industryAntifungal Agents/ therapeutic useCandidiasisMicafunginGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseApacheSurgeryTreatment OutcomechemistryMicafunginFemaleCaspofunginbusinessFluconazolemedicine.drugThe Lancet
researchProduct

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Res…

2010

Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neut…

AdultMalemedicine.medical_specialtyAntifungal AgentsDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationAspergillosischemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultPharmacotherapyCaspofunginInternal medicineMedicineAspergillosisHumansTransplantation HomologousaspergillosiscaspofunginAdverse effectSurvival rateAgedallogeneicTransplantationbusiness.industryHematopoietic Stem Cell Transplantationhematopoietic SCTHematologyMiddle Agedmedicine.diseaseSurgeryCalcineurinTransplantationEuropeSurvival RateTreatment OutcomechemistryDrug Therapy CombinationFemaleCaspofunginbusinessBone marrow transplantation
researchProduct

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

Phenotypic analysis of peripheral lymphocyte subpopulations in hydatid patients.

1999

Peripheral T-lymphocytes were analyzed in three groups of people: (1) individuals with current liver hydatid disease (hydatid patients, n = 20), (2) persons who had undergone surgical cyst removal at least 2 years previously (recovered patients, n = 9), and (3) a control group of healthy volunteers (uninfected controls, n = 13). Group 1 was subdivided according to cyst status, relapse of disease, and the presence or absence of symptoms. Percentages of lymphocytes expressing CD3, CD4, CD8, CD56, CD25, CD45RA, CD45RO, and HLA-DR were determined. Symptomatic patients had proportionally fewer CD3+ CD8 + lymphocytes than the control group (P=0.038). Hydatid patients with active cysts had proport…

AdultMalemedicine.medical_specialtyPathologyEchinococcosis HepaticHelminthiasischemical and pharmacologic phenomenaBiologyGastroenterologyNatural killer cellImmunophenotypingImmune systemAntigens CDT-Lymphocyte SubsetsInternal medicineparasitic diseasesmedicineHumansCystIL-2 receptorEchinococcus granulosusAgedGeneral VeterinaryGeneral MedicineT lymphocyteMiddle Agedmedicine.diseasebiology.organism_classificationInfectious Diseasesmedicine.anatomical_structureInsect ScienceLeukocytes MononuclearParasitologyFemaleCD8Parasitology research
researchProduct

Analysis of cytokine and specific antibody profiles in hydatid patients with primary infection and relapse of disease

1998

We studied in vitro cytokine production by peripheral blood mononuclear cells (PBMC) from patients with primary and recurrent hydatid disease when cells were incubated with mitogen (PHA) and antigen from hydatid cyst fluid (HCFAg); levels of specific IgE, IgG4 and eosinophil counts were also measured in sera. When specifically stimulated, PBMC from patients produced higher levels of IL-2 (P < 0.02), IFN-γ (P < 0.0028) and IL-5 (P < 0.01) than those from uninfected donors, whereas IL-10 levels were comparable. Notably, IL-5 was also produced in higher levels (P < 0.01) by PBMC from patients when incubated with PHA. The IL-5:IFN-γ ratio was significantly greater (P < 0.02) when measured in re…

AdultMalemedicine.medical_treatmentImmunologyAntibodies HelminthBlood DonorsCell CountStimulationDiseaseImmunoglobulin EPeripheral blood mononuclear cellAntigenEchinococcosisRecurrencemedicineAnimalsHumansPhytohemagglutininsCells CulturedAgedbiologybusiness.industryMiddle AgedEosinophilIn vitroEosinophilsmedicine.anatomical_structureCytokineAntigens HelminthImmunologyLeukocytes Mononuclearbiology.proteinCytokinesCattleFemaleParasitologyMitogensbusinessCell DivisionParasite Immunology
researchProduct

Multimodality imaging in cardiac echinococcosis for diagnosis and follow-up of an untreatable cyst

2016

Adultmedicine.medical_specialtyCardiac magnetic resonance (CMR)030204 cardiovascular system & hematologyMultimodal ImagingImagingFollow-Up Studie03 medical and health sciences0302 clinical medicinemedicineCyst030212 general & internal medicineMultimodal imagingbiologybusiness.industryFollow up studiesEchinococcumedicine.diseasebiology.organism_classificationEchinococcosisCystHeart DiseaseEchinococcusTrans-thoracic echocardiogram (TTE)EchinococcosiRadiologyCardiology and Cardiovascular MedicinebusinessCardiacHumanInternational Journal of Cardiology
researchProduct

Heterogeneity in Cystic Echinococcosis Management Among Spanish Centers: Results from a National Survey

2020

The aim of the study was to evaluate the availability of different procedures, diagnostic tests, and treatments, as well as the procedures and techniques used in the management of cystic echinococcosis (CE) in Spain. This was a cross-sectional study performed from September to December 2018 in Spain. A survey directed to CE-treating clinicians was conducted to collect information regarding the center characteristics and the different protocols of management followed. Thirty-nine centers among 76 contacted centers participated in the survey, most of them belonging to the public health system and attending both adult and children. The median number of patients with CE attended during the last…

Adultmedicine.medical_specialtyReferral030231 tropical medicineMEDLINEEmigrants and ImmigrantsPercutaneous techniques03 medical and health sciences0302 clinical medicineWho recommendationsEchinococcosisVirologymedicineHumansNational levelChildCystic echinococcosisbusiness.industryPublic healthAge FactorsDiagnostic testArticlesHealth SurveysCross-Sectional StudiesInfectious DiseasesSpainFamily medicineParasitologybusiness
researchProduct